• KOLs Community
    • Lentigo
    • Lentigo Maligna
    • Martijn B A Doorn
    • Martijn B A Doorn

      Martijn B A Doorn

      Department of Dermatology, Erasmus Medical Centre, Rotterdam, The Netherlands | Department of Dermatology, Erasmus MC, Rotterdam, The Netherlands | Centre for Human Drug ...



      KOL Resume for Martijn B A Doorn


      Department of Dermatology, Erasmus Medical Centre, Rotterdam, The Netherlands


      Department of Dermatology, Erasmus University Medical Center, Rotterdam, the Netherlands


      Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands


      Department of Dermatology Erasmus MC University Medical Center Rotterdam Rotterdam The Netherlands


      Department of Dermatology, Erasmus University Medical Center, 3000, CA, Rotterdam, the Netherlands


      Department of Dermatology, Erasmus MC, Rotterdam, the Netherlands


      Department of Dermatology, Erasmus MC University Medical Centre, Rotterdam, The Netherlands



      Martijn B A Doorn: Influence Statistics

      Sample of concepts for which Martijn B A Doorn is among the top experts in the world.
      Concept World rank
      trial omiganan #8
      nonlesional skin microbiota #8
      morning itch #8
      omiganan atopic dematitis #8
      imiquimod‐induced inflammatory #9
      omn combination #9
      omn increases #9
      volunteers omiganan #9
      imiquimod omn #9
      omn imq #9
      load dermatitis #9
      omiganan omn #9
      imq increases #9
      treatment omn #9
      imq omn #9
      omn addon treatment #9
      omn enhanced #9
      enhanced omn #9
      enhances imiquimod‐induced #9
      omn inflammatory response #9
      omiganan enhances #10
      methotrexate prospective studies #12
      topical omiganan #13
      patients topical omiganan #13
      removal hidradenitis #13
      concept study skin #13
      topical omiganan patients #13
      observed omiganan #14
      omiganan 25 #14
      omiganan daily #14
      omiganan treatment groups #14
      omiganan patients #18
      omiganan treatment #19
      indolicidin analog #20
      palmoplantar pasi #20
      treatment palmoplantar psoriasis #22
      inflammatory response imq #23
      microbiota placebos #23
      dermatitis small #29
      imq tlr7 #30
      gel 95 #36
      combining biologics #36
      cream lidocaine #37
      synthetic cationic peptide #39
      contrast vehicle #44
      topical imq #46
      patients palmoplantar psoriasis #47
      response imq #54
      viral skin diseases #71
      insensible young adult #73


      Prominent publications by Martijn B A Doorn

      KOL-Index: 8109

      BACKGROUND: Lentigo maligna is a slowly growing melanoma in situ. Current guidelines advise wide local excision with a margin of 5 mm as the treatment of first choice, which has recurrence rates ranging from 6% to 20%.

      OBJECTIVES: To determine retrospectively the recurrence rate of lentigo maligna after staged surgical excision.

      METHODS: Records of all patients with lentigo maligna treated with our method of staged surgical excision between 2002 and 2011 were retrieved. To identify ...

      Known for Lentigo Maligna | Surgical Excision | Recurrence Rate | Treatment Choice | Female Head
      KOL-Index: 5661

      BACKGROUND: Secukinumab has shown sustained efficacy and safety in several manifestations of psoriasis.

      OBJECTIVES: GESTURE investigated the long-term (2·5-year) safety and efficacy of 150 mg and 300 mg subcutaneous secukinumab in 205 patients with moderate-to-severe palmoplantar psoriasis.

      METHODS: GESTURE was a randomized, double-blind, placebo-controlled, multicentre, phase IIIb trial conducted across 15 countries. The study was 140 weeks long and consisted of four periods: screening ...

      Known for Palmoplantar Psoriasis | Monoclonal Antibodies | Secukinumab Patients | 16 Weeks | Life Severity
      KOL-Index: 3449

      Biological drugs such as the tumour necrosis factor inhibitors have revolutionized the treatment of psoriasis, but some have the potential to induce an unwanted immune response. This immunogenicity may be associated with low trough drug levels, reduced clinical efficacy, reduced drug survival and an increased risk for adverse events. This article presents a literature review of the evidence on immunogenicity of biologics used in the treatment of psoriasis and considers the implications ...

      Known for Treatment Psoriasis | Biological Drugs | Necrosis Factor | Literature Review | Immunogenicity Biologics
      KOL-Index: 2900

      Imiquimod (IMQ) is often used as a topical challenge agent to provoke local skin inflammation. The objective of this study was to develop and refine a rapid, temporary, and reversible human skin inflammation model with IMQ for application in clinical drug development. A randomized, vehicle-controlled, open-label, dose-ranging study was conducted in 16 healthy male subjects. IMQ (5 mg) was applied once daily for 72 hours under occlusion to intact skin (n = 8) or tape stripped (TS) skin (n ...

      Known for Imiquimod Imq | Skin Inflammation | Publication Administration | Insensible Young Adult | Volunteers Humans
      KOL-Index: 2417

      Omiganan (OMN; a synthetic cationic peptide) and imiquimod (IMQ; a TLR7 agonist) have synergistic effects on interferon responses in vitro. The objective of this study was to translate this to a human model for proof-of-concept, and to explore the potential of OMN add-on treatment for viral skin diseases. Sixteen healthy volunteers received topical IMQ, OMN, or a combination of both for up to 4 days on tape-stripped skin. Skin inflammation was quantified by laser speckle contrast imaging ...

      Known for Imq Treatment | 95 Confidence Interval | Antimicrobial Cationic | Adult Administration | Humans Imiquimod
      KOL-Index: 1882
      Known for Lentigo Maligna | Laser Therapy | Nose Neoplasms | Humans Hutchinson | Melanotic Freckle
      KOL-Index: 1825

      Omiganan is an indolicidin analog with antimicrobial properties that could be beneficial for patients with atopic dermatitis. In this randomized, double-blind, placebo-controlled, phase II trial we explored the efficacy, pharmacodynamics, and safety of topical omiganan once daily in 36 patients with mild to moderate atomic dermatitis. Patients were randomized to apply topical omiganan 1%, omiganan 2.5%, or vehicle gel to one target lesion once daily for 28 consecutive days. Small but ...

      Known for Atopic Dermatitis | Publication Administration | Antimicrobial Cationic | Staphylococcus Aureus
      KOL-Index: 1463
      Known for Methotrexate Psoriasis | Combination Humans | Drug Therapy | Dermatologic Agents | Biological Products
      KOL-Index: 1032

      Pain is a common side-effect of dermatological laser procedures. Non-invasive anaesthetic drugs and anaesthetic procedures can be used to provide pain relief and increase patient satisfaction and treatment efficacy. However, it remains unclear which method provides the best pain relief. The objective of this systematic review was therefore to assess the efficacy and safety of non-invasive anaesthetic methods during dermatological laser procedures. A systematic literature search was ...

      Known for Laser Therapy | Anesthetics Local | Pain Common | Controlled Clinical | Assess Efficacy
      KOL-Index: 986

      BACKGROUND: Pain is a common adverse effect of dermatological laser procedures. Currently, no standard topical anaesthetic cream exists for deeper dermal laser procedures.

      OBJECTIVES: To compare the efficacy of lidocaine/tetracaine cream and lidocaine/prilocaine cream in reducing self-reported pain during deeper dermal laser treatment of acne keloidalis nuchae (AKN) and tattoos.

      METHODS: We conducted two randomized, double-blind, controlled clinical trials with intrapatient, split-lesion ...

      Known for Laser Treatment | Anesthetics Local | Visual Analogue
      KOL-Index: 743
      Known for Hidradenitis Suppurativa | Hair Removal | Laser Therapy

      Key People For Lentigo Maligna

      Top KOLs in the world
      Arthur J Sober
      cutaneous melanoma clinical stage united states
      Glen M Bowen
      lentigo maligna merkel cell carcinoma paraneoplastic pemphigus
      Alfred W Kopf
      malignant melanoma tumor conference basal cell
      Martin C Mihm
      malignant melanoma skin neoplasms clinical stage
      JOHN ALBERT Zitelli
      mohs micrographic surgery surgical margins frozen sections
      Klaus J Busam
      situ hybridization desmoplastic melanoma mohs surgery

      Martijn B A Doorn:Expert Impact

      Concepts for whichMartijn B A Doornhas direct influence:Lentigo maligna,  Palmoplantar psoriasis,  Topical omiganan,  Surgical excision,  Atopic dermatitis,  Recurrence rate,  Omiganan enhances,  Secukinumab patients.

      Martijn B A Doorn:KOL impact

      Concepts related to the work of other authors for whichfor which Martijn B A Doorn has influence:Lentigo maligna,  Drug survival,  Hidradenitis suppurativa,  Psoriatic arthritis,  Atopic dermatitis,  Psoriasis patients,  Hereditary angioedema.



      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Department of Dermatology, Erasmus Medical Centre, Rotterdam, The Netherlands | Department of Dermatology, Erasmus MC, Rotterdam, The Netherlands | Centre for Human Drug Research, Leiden, The Netherlands | Department of Dermatology, Erasmus Universit

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.